Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Retatrutide: Evidence Summary
Evidence summary for Retatrutide across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Retatrutide overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Weight loss (obesity) | Tier B | 2 | Phase 2 trial showed up to 24% body weight reduction at 48 weeks — Phase 3 TRIUMPH program ongoing |
| Type 2 diabetes | Tier B | 2 | Significant HbA1c reduction (-2.0%) in Phase 2; triple agonism provides enhanced metabolic benefits |
| NASH/MASH | Tier C | 1 | Reduced liver fat content observed as secondary endpoint in Phase 2 |
References (6)
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. — Coskun T, Wu Q, Schloot NC, Haupt A, Milicevic Z, et al. . The lancet. Diabetes & endocrinology (2025) PMID: 40609566
- Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study. — Kanu C, Boye KS, Poon JL, Goetz I, Williamson S, et al. . Diabetes, obesity & metabolism (2025) PMID: 40916752
- Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials. — Misra S, Narayan RK, Kaur M . Journal of basic and clinical physiology and pharmacology (2025) PMID: 40728138
- Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis. — Tewari J, Qidwai KA, Tewari A, Kaur S, Tewari V, et al. . Expert review of clinical pharmacology (2025) PMID: 39817343
- Comparative Meta-Analysis of Retatrutide Versus Placebo and Dulaglutide for Weight Loss and Diabetes Management. — Ayesh H, Ayesh S, Niswender K . American journal of therapeutics (2024) PMID: 38976545
- Triple Agonism Based Therapies for Obesity. — Goldney J, Hamza M, Surti F, Davies MJ, Papamargaritis D . Current cardiovascular risk reports (2025) PMID: 40741227